Cargando…
Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
Autores principales: | Tran, Thi Ha Chau, Dumas, Stéphane, Coscas, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079526/ https://www.ncbi.nlm.nih.gov/pubmed/30116636 http://dx.doi.org/10.1155/2018/9171269 |
Ejemplares similares
-
Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017) -
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022) -
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021) -
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
Publicado: (2017)